About Kai Lipinski
Kai comes from an impressive background in viral vector manufacturing. Currently, he is the Chief Scientific Officer at Vibalogics where he leads process development and manufacturing capabilities, technology evaluations, and the oversight of client technical relationships. In previous roles he was responsible for the upstream process development of virus and mammalian protein expression projects, as well as the development of targeted adenoviral vectors for gene therapy approaches to cancer. Kai holds a PhD in Transcriptional Regulation by Adenoviral E1A Proteins from the University of Duisburg- Essen.
Why Genezen? I am excited to accompany Genezen’s catapulted development under the Ampersand Capital Partners’ umbrella, establishing their own in-house development and manufacturing capacities. People with big visions and missions are determined to succeed for their clients and patients in need. With this clear focus and passion, I believe Genezen will become an industry leader for international lentiviral and retroviral supply.
I’m passionate about Meeting the enormous need for lentiviral and retroviral manufacture in order to enable long-term and stable cures for cancer and well-characterized genetic diseases.
Meet our People
Our team is dedicated to getting your viral vector where it needs to go. Communication and collaboration are part of our DNA and we can't wait to talk to you about your current challenges and needs.